RU2020131492A - Method for the treatment of osteoarthritis and the composition of substances for its implementation - Google Patents

Method for the treatment of osteoarthritis and the composition of substances for its implementation Download PDF

Info

Publication number
RU2020131492A
RU2020131492A RU2020131492A RU2020131492A RU2020131492A RU 2020131492 A RU2020131492 A RU 2020131492A RU 2020131492 A RU2020131492 A RU 2020131492A RU 2020131492 A RU2020131492 A RU 2020131492A RU 2020131492 A RU2020131492 A RU 2020131492A
Authority
RU
Russia
Prior art keywords
blocker
composition according
ion channels
calcium ion
amount
Prior art date
Application number
RU2020131492A
Other languages
Russian (ru)
Other versions
RU2020131492A3 (en
Inventor
Олег Владимирович Коломыткин
Original Assignee
Олег Владимирович Коломыткин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олег Владимирович Коломыткин filed Critical Олег Владимирович Коломыткин
Priority to RU2020131492A priority Critical patent/RU2020131492A/en
Priority to PCT/RU2021/000253 priority patent/WO2022066042A1/en
Publication of RU2020131492A3 publication Critical patent/RU2020131492A3/ru
Publication of RU2020131492A publication Critical patent/RU2020131492A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Claims (12)

1. Способ лечения остеоартроза, в котором совместно инъецируют в больной сустав блокатор кальциевых ионных каналов, расположенных в цитоплазматической мембране клетки, и блокатор иных кальциевых каналов, расположенных в мембране эндоплазматического ретикулума и других клеточных органелл.1. A method for the treatment of osteoarthritis, in which a blocker of calcium ion channels located in the cytoplasmic membrane of a cell and a blocker of other calcium channels located in the membrane of the endoplasmic reticulum and other cell organelles are jointly injected into the diseased joint. 2. Способ по п. 1, отличающийся тем, что количество инъекций в течение одного курса лечения устанавливают от 1 до 3 с интервалом от 1 до 3 недель, адаптированных для пациента.2. The method according to claim 1, characterized in that the number of injections during one course of treatment is set from 1 to 3 with an interval of 1 to 3 weeks, adapted to the patient. 3. Композиция веществ для лечения остеоартроза, содержащая блокатор кальциевых ионных каналов, расположенных в цитоплазматической мембране, и блокатор иных кальциевых ионных каналов, расположенных в мембране эндоплазматического ретикулума и других внутриклеточных органелл.3. A composition of substances for the treatment of osteoarthritis, containing a blocker of calcium ion channels located in the cytoplasmic membrane, and a blocker of other calcium ion channels located in the membrane of the endoplasmic reticulum and other intracellular organelles. 4. Композиция по п. 3, отличающаяся тем, что содержание ингибиторов в ней составляет от 0,001 до 2,5 мг, а содержание дополнительных блокаторов составляет от 0,001 до 2,5 мг.4. The composition according to claim 3, characterized in that the content of inhibitors in it is from 0.001 to 2.5 mg, and the content of additional blockers is from 0.001 to 2.5 mg. 5. Композиция по п. 4, отличающаяся тем, что она содержит фармацевтически приемлемый носитель объемом от 0,1 до 5 мл.5. Composition according to claim. 4, characterized in that it contains a pharmaceutically acceptable carrier with a volume of from 0.1 to 5 ml. 6. Композиция по п. 3, отличающаяся тем, что она содержит дантролен в количестве от 0,001 до 2,5 мг в качестве блокатора выхода ионов кальция из эндоплазматического ретикулума.6. The composition according to claim 3, characterized in that it contains dantrolene in an amount of 0.001 to 2.5 mg as a blocker for the release of calcium ions from the endoplasmic reticulum. 7. Композиция по п. 3, отличающаяся тем, что она содержит прокаин в количестве от 0,001 до 2,5 мг в качестве блокатора выхода ионов кальция из эндоплазматического ретикулума.7. The composition according to claim 3, characterized in that it contains procaine in an amount of 0.001 to 2.5 mg as a blocker for the release of calcium ions from the endoplasmic reticulum. 8. Композиция по п. 3, отличающаяся тем, что в качестве блокатора кальциевых ионных каналов цитоплазматической мембраны используют нифедипин в количестве от 0,001 до 2,5 мг.8. Composition according to claim 3, characterized in that nifedipine is used as a blocker of calcium ion channels of the cytoplasmic membrane in an amount of from 0.001 to 2.5 mg. 9. Композиция по п. 3, отличающаяся тем, что в качестве блокатора кальциевых ионных каналов цитоплазматической мембраны используют верапамил в количестве от 0,001 до 2,5 мг.9. Composition according to claim 3, characterized in that verapamil is used as a blocker of calcium ion channels of the cytoplasmic membrane in an amount of 0.001 to 2.5 mg. 10. Композиция по п. 3, отличающаяся тем, что в качестве блокатора кальциевых ионных каналов цитоплазматической мембраны используют дилтиазем в количестве от 0,001 до 2,5 мг.10. The composition according to claim 3, characterized in that diltiazem is used as a blocker of calcium ion channels of the cytoplasmic membrane in an amount of 0.001 to 2.5 mg. 11. Композиция по п. 3, отличающаяся тем, что она содержит физиологический водный солевой раствор объемом от 0,1 до 5 мл в качестве носителя.11. Composition according to claim. 3, characterized in that it contains a physiological aqueous saline solution with a volume of from 0.1 to 5 ml as a carrier. 12. Композиция по п. 3, отличающаяся тем, что она содержит визкосаплемент в концентрации от 0,01 до 1 г/л в качестве носителя.12. Composition according to claim. 3, characterized in that it contains viscosupplement at a concentration of 0.01 to 1 g/l as a carrier.
RU2020131492A 2020-09-24 2020-09-24 Method for the treatment of osteoarthritis and the composition of substances for its implementation RU2020131492A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2020131492A RU2020131492A (en) 2020-09-24 2020-09-24 Method for the treatment of osteoarthritis and the composition of substances for its implementation
PCT/RU2021/000253 WO2022066042A1 (en) 2020-09-24 2021-06-16 Method for treating osteoarthritis and composition of substances for embodying thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020131492A RU2020131492A (en) 2020-09-24 2020-09-24 Method for the treatment of osteoarthritis and the composition of substances for its implementation

Publications (2)

Publication Number Publication Date
RU2020131492A3 RU2020131492A3 (en) 2022-03-24
RU2020131492A true RU2020131492A (en) 2022-03-24

Family

ID=80815969

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020131492A RU2020131492A (en) 2020-09-24 2020-09-24 Method for the treatment of osteoarthritis and the composition of substances for its implementation

Country Status (2)

Country Link
RU (1) RU2020131492A (en)
WO (1) WO2022066042A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
RU2344823C2 (en) * 2006-04-10 2009-01-27 Юрий Александрович Курилов Method of arthrosis deformans or polyarticular rheumatoid arthritis treatment

Also Published As

Publication number Publication date
RU2020131492A3 (en) 2022-03-24
WO2022066042A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
RU2010118022A (en) PHARMACEUTICAL COMPOSITION OF VALSARTAN
JP2010525033A5 (en)
RU2003116058A (en) COMPOSITIONS OF A HYDROCODON WITH CONTROLLED RELEASE
RU2013109136A (en) DOSAGE FORM THAT CONTAINS 6'-FLUOR- (N-METHYL-OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'N-SPIRO [CYCLOGEXAN-1,1'- PIRANO [3,4, b] INDOL] -4-AMIN
US20080255499A1 (en) Compositions for Peritoneal Dialysis
RU2020131492A (en) Method for the treatment of osteoarthritis and the composition of substances for its implementation
JP2018538243A5 (en)
RU2002119210A (en) Oxcarbazepine Suspension
RU2018134132A (en) VISCOELASTIC LIRAGLUTIDE GEL ADAPTED FOR ONE-WEEKLY OR ONE-TIME TWO-WAY APPLICATION
RU2021109694A (en) Method for the treatment of osteoarthritis and the composition of substances for its implementation
Leng-Peschlow Sennoside-induced secretion and its relevance for the laxative effect
RU2010101634A (en) METHOD FOR OPTIMIZING TREATMENT OF CHRONIC MYELOLEukOSIS BY ABI TRIROZINKINASE INHIBITORS
RU2002129588A (en) NEW DRUGS OF ALPHA -2,4-DISULFOPHENYL-N-TRET-BUTYLNITRON
BG66222B1 (en) Dialysis composition
Miller et al. Severe hyperkalemia during piroxicam therapy
RU2006114834A (en) INFUSION DRUG CONTAINING (2R) -2-PROPYLOCTANIC ACID AS AN ACTIVE INGREDIENT
Zhang et al. Unilateral horizontal semicircular canal occlusion induces serotonin increase in medial vestibular nuclei: a study using microdialysis in vivo coupled with HPLC–ECD
RU2163115C2 (en) Composition for chemically widening dental canals
CN101491495A (en) Salvianolic acid B magnesium injection, preparation method and use thereof
JPH0737388B2 (en) Renal function improving agent
JP2017039687A (en) Nalfurafine hydrochloride-containing capsule formulation
CN101554370A (en) Syringin for injection, preparation method and application thereof
Guan et al. Abnormal contractile response of aortas from spontaneously hypertensive rats to Ca2+ after depletion of Ca2+ in Ca2+-free medium
Fraile Mirtazapine/tacrolimus interaction Hypotension in an elderly patient following renal
Morelli et al. Action of Litonotus (predator) toxicysts on the electric properties of Euplotes (prey) cell membrane